

Media release

PolyPeptide publishes invitation to the annual General Meeting 2024

Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, published today the invitation to the third annual General Meeting which will take place on 10 April 2024 at the Chollerhalle in Zug.

At PolyPeptide Group AG's (the "Company") third annual General Meeting which will take place on 10 April 2024 at the Chollerhalle in Zug (the "AGM 2024"), six current members of the Board of Directors will stand for re-election. Dorothee A. Deuring has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Ms. Deuring for her contribution. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee.

The Board of Directors further proposes to the AGM 2024 the deletion of art. 25 para. 3 of the Company's Articles of Association relating to the aggregate compensation for consulting services to the Company provided by members of the Board of Directors. The proposed deletion shall eliminate any concerns regarding a possible impairment of the objectivity and independence of the members of the Board of Directors.

Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2023 as well as the Remuneration Report 2023 and the report on non-financial matters for the financial year 2023, both in separate consultative votes.

The invitation to the AGM 2024 with the detailed proposals and explanations can be found on the Company's [website](#).

Contact

PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com
T: +41 43 502 05 80

About PolyPeptide

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.

@PolyPeptide – follow us on [LinkedIn](#)

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.